Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Revenue of Inhibrx, Inc. (INBX)
Revenue in 2023 (TTM): $1.8 M
According to Inhibrx, Inc.'s latest financial reports the company's current revenue (TTM) is $1.8 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Inhibrx, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $1.8 M | $609 K | $-218,030,000 | $-239,724,000 | $-241,361,000 |
| 2022 | $2.18 M | $-668,000 | $-129,117,000 | $-145,223,000 | $-145,226,000 |
| 2021 | $7.13 M | $4.44 M | $-76,564,000 | $-81,766,000 | $-81,768,000 |
| 2020 | $12.81 M | $-60,687,000 | $-67,443,000 | $-75,634,000 | $-75,637,000 |
| 2019 | $9.09 M | $-38,814,000 | $-42,604,000 | $-50,502,000 | $-51,400,000 |
| 2018 | $7.5 M | $-25,954,000 | $-28,769,000 | $-30,925,000 | $-31,163,000 |
| 2017 | $7.95 M | $-17,560,000 | $-19,305,000 | $-21,830,000 | $-19,442,000 |
| 2016 | $6.67 M | $-10,325,000 | $-11,893,000 | $-12,885,000 | $-8,269,000 |